April 30, 2024 11:02 AM EDT
R&D
Pharma

Lil­ly scraps tri­als of Verzenio, Jar­diance and a gene ther­a­py from Pre­vail

Kyle LaHucik

Senior Reporter

As part of its quar­ter­ly clean­ing, Eli Lil­ly re­moved a few tri­als from its pipeline, in­clud­ing late-stage stud­ies of ap­proved can­cer drug Verzenio and its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J's new can­cer com­bo beats As­traZeneca's Tagris­so on sur­vival in lung tri­al

FDA sets an ef­fi­ca­cy thresh­old for fu­ture weight loss drugs

Sanofi part­ners with Al­loy Ther­a­peu­tics to make new CNS drug

Cal­i­co, De­nal­i's ALS drugs miss pri­ma­ry ob­jec­tives in bas­ket study

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

Ver­tex signs in vi­vo gene edit­ing de­liv­ery pact for sick­le cell and tha­lassemia as it looks be­yond Cas­gevy

A service from the Financial Times